Caplan Arnold I
Skeletal Research Center, Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA.
Tissue Eng. 2005 Jul-Aug;11(7-8):1198-211. doi: 10.1089/ten.2005.11.1198.
Adult stem cells provide replacement and repair descendants for normal turnover or injured tissues. These cells have been isolated and expanded in culture, and their use for therapeutic strategies requires technologies not yet perfected. In the 1970s, the embryonic chick limb bud mesenchymal cell culture system provided data on the differentiation of cartilage, bone, and muscle. In the 1980s, we used this limb bud cell system as an assay for the purification of inductive factors in bone. In the 1990s, we used the expertise gained with embryonic mesenchymal progenitor cells in culture to develop the technology for isolating, expanding, and preserving the stem cell capacity of adult bone marrow-derived mesenchymal stem cells (MSCs). The 1990s brought us into the new field of tissue engineering, where we used MSCs with site-specific delivery vehicles to repair cartilage, bone, tendon, marrow stroma, muscle, and other connective tissues. In the beginning of the 21st century, we have made substantial advances: the most important is the development of a cell-coating technology, called painting, that allows us to introduce informational proteins to the outer surface of cells. These paints can serve as targeting addresses to specifically dock MSCs or other reparative cells to unique tissue addresses. The scientific and clinical challenge remains: to perfect cell-based tissue-engineering protocols to utilize the body's own rejuvenation capabilities by managing surgical implantations of scaffolds, bioactive factors, and reparative cells to regenerate damaged or diseased skeletal tissues.
成体干细胞为正常更新或受损组织提供替代和修复后代细胞。这些细胞已在培养中分离和扩增,而将其用于治疗策略需要尚未完善的技术。20世纪70年代,胚胎鸡肢体芽间充质细胞培养系统提供了有关软骨、骨和肌肉分化的数据。20世纪80年代,我们将这个肢体芽细胞系统用作一种检测方法,以纯化骨中的诱导因子。20世纪90年代,我们利用在培养胚胎间充质祖细胞过程中积累的专业知识,开发了用于分离、扩增和保存成人骨髓来源的间充质干细胞(MSC)干细胞能力的技术。20世纪90年代将我们带入了组织工程的新领域,在那里我们使用MSC与位点特异性递送载体来修复软骨、骨、肌腱、骨髓基质、肌肉和其他结缔组织。在21世纪初,我们取得了重大进展:最重要的是开发了一种称为“涂绘”的细胞包被技术,该技术使我们能够将信息蛋白引入细胞外表面。这些涂料可以作为靶向地址,将MSC或其他修复细胞特异性对接至独特的组织地址。科学和临床方面的挑战仍然存在:完善基于细胞的组织工程方案,通过管理支架、生物活性因子和修复细胞的手术植入来利用身体自身的修复能力,以再生受损或患病的骨骼组织。